DATEASSETTITLELEAD AUTHORJOURNAL
09 Dec 2024ISB 2001First Results of a Phase 1, First-in-Human, Dose Escalation Study of ISB 2001, a BCMAxCD38xCD3 Targeting Trispecific Antibody in Patients with Relapsed/Refractory Multiple Myeloma (RRMM)Quach H. et al.
 American Society of Hematology Annual Meeting - Head of Information Technologyarrow_green
08 Dec 2024ISB 1442Dose Escalation of ISB 1442, a Novel CD38 Biparatopic x CD47 Bispecific Antibody, in Patients with Relapsed / Refractory Multiple MyelomaDhakal, B. et al.
American Society of Hematology Annual Meetingarrow_green
09 Nov 2024GRC 65327Poster: GRC 65327, a novel small molecule selective Cbl-b inhibitor for solid tumorsChaudhari, S. et al.
Society for Immunotherapy of Cancerarrow_green
11 Sep 2024ISB 2001ISB 2001 trispecific T cell engager shows strong tumor cytotoxicity and overcomes immune escape mechanisms of multiple myeloma cellsCarretero-Iglesia L. et al.
Nature Cancerarrow_green
20 Jun 2024BEAT® Antibody Engineering PlatformDevelopment of a 10 g/L process for a difficult-to-express multispecific antibody format using a holistic process development approachPeltret M. et al.
Journal of Biotechnology
arrow_green
22 Apr 2024BEAT® Antibody Engineering PlatformAlternative splicing for tuneable expression of protein subunits at desired ratios
Aebischer-Gumy C. et al.
mAbsarrow_green
07 Apr 2024ISB 2001Oral Presentation: ISB 2001, a BCMA and CD38 dual targeting T-cell engager, demonstrates superior cytotoxicity relative to teclistamab in the samples of patients relapsing from CD38 and BCMA targeted immunotherapies
Perro, M. et al.American Association for Cancer Research Annual Meetingarrow_green
06 Mar 2024ISB 1442Development of ISB 1442, a CD38 and CD47 bispecific biparatopic antibody innate cell modulator for the treatment of multiple myeloma
Grandclément C. et al.
Nature Communications
arrow_green
11 Dec 2023ISB 1442Poster: Initial Dose Escalation of ISB 1442, a Novel CD38 Biparatopic x CD47 Bispecific Antibody, in Patients with Relapsed/Refractory Multiple Myeloma (RRMM)
Kazandjian D. et al.American Society of Hematology Annual Meetingarrow_green
10 Dec 2023ISB 1342Poster: Dose Escalation of ISB 1342, a Novel CD38xCD3 Bispecific Antibody, in Patients with Relapsed/Refractory Multiple Myeloma (RRMM)
Kapoor P. et al.American Society of Hematology Annual Meetingarrow_green
10 Dec 2023ISB 2001Poster: A Phase 1, First-in-Human, Dose Escalation and Dose-Expansion Study of a BCMAxCD38xCD3 Targeting Trispecific Antibody ISB 2001 in Subjects with Relapsed/Refractory Multiple Myeloma (RRMM)Sia H. et al.American Society of Hematology Annual Meetingarrow_green
05 Nov 2023GRC 54276Clinical Abstract: Phase 1 First In Human Study Evaluating The Safety, Tolerability, Pharmacokinetics And Efficacy Of Grc 54276, A Novel HPK1 Thronine-Kinase Inhibitor, In Advanced Solid Tumours And Lymphomas.Doddihal H. et. al.European Hematology Associationarrow_green
22 May 2023ISB 1342Pre-clinical Characterization of ISB 1342, a CD38xCD3 T-cell Engager for Relapsed/Refractory Multiple MyelomaPerro M. et al.Bloodarrow_green
17 Apr 2023ISB 2001Overcoming Mechanisms of Escape from Treatments for Multiple Myeloma by ISB 2001, a first-in-Class Trispecific BCMA and CD38 targeted T Cell EngagerPerro M. et al.American Association for Cancer Research Annual Meetingarrow_green
12 Dec 2022ISB 1442Poster: A Phase 1/2, First-in-Human, Multicenter, Open-Label, Dose Escalation and Dose- Expansion Study of Single-Agent ISB 1442 in Patients with Relapsed/Refractory Multiple MyelomaJiang T. et al.American Society of Hematology Annual Meetingarrow_green
12 Dec 2022ISB 1442Poster: A Phase 1/2, First-in-Human, Multicenter, Open-Label, Dose Escalation and Dose- Expansion Study of Single-Agent ISB 1442 in Patients with Relapsed/Refractory Multiple MyelomaJiang T. et al.American Society of Hematology Annual Meetingarrow_green
11 Dec 2022ISB 1342Poster: Initial Results of Dose Escalation of ISB 1342, a Novel CD3xCD38 Bispecific Antibody, in Patients with Relapsed / Refractory Multiple Myeloma (RRMM)Mohan S. et al.American Society of Hematology Annual Meetingarrow_green
11 Dec 2022ISB 1342Poster: Initial Results of Dose Escalation of ISB 1342, a Novel CD3xCD38 Bispecific Antibody, in Patients with Relapsed / Refractory Multiple Myeloma (RRMM)Mohan S. et al.American Society of Hematology Annual Meetingarrow_green
11 Dec 2022ISB 1442Poster: Preclinical Evaluation of ISB 1442, a First-in-Class CD38 and CD47 Bispecific Antibody Innate Cell Modulator for the Treatment of AML and T-ALLSammicheli S. et al.American Society of Hematology Annual Meetingarrow_green
11 Dec 2022ISB 1442Presentation: Preclinical Evaluation of ISB 1442, a First-in-Class CD38 and CD47 Bispecific Antibody Innate Cell Modulator for the Treatment of AML and T-ALLSammicheli S. et al.Presentation at the American Society of Hematology Annual Meetingarrow_green
10 Dec 2022ISB 2001ISB 2001, a First-in-Class Trispecific BCMA and CD38 T Cell Engager Designed to Overcome Mechanisms of Escape from Treatments for Multiple Myeloma by Targeting Two AntigensPerro M. et al.Presentation at the American Society of Hematology Annual Meetingarrow_green
28 Jun 2022Process DevelopmentOptimization of a Cell Culture Clarification Platform Process With the Aim of Boosting the Recovery of Bispecific AntibodiesMette R. et al.ESACT2022 Conferencearrow_green
28 Jun 2022Process DevelopmentIncreased Throughput in Upstream Development via Automated Feed Strategy Using Qubicon®Schmid S. et al.ESACT2022 Conferencearrow_green
27 Jun 2022Process DevelopmentAssessment Of The Impact Of The Milling Type And Production Site For Cell Culture Feed Production Le Moal M. et al.ESACT2022 Conferencearrow_green
10 Jun 2022ISB 1442ISB 1442, a First-in-Class CD38 and CD47 Bispecific Antibody Innate Cell Modulator for the Treatment of CD38+ Malignancies Sammicheli S. et al.EHA2022arrow_green
13 Apr 2022ISB 1442ISB 1442, a First-in-Class CD38 and CD47 Bispecific Antibody Innate Cell Modulator for the Treatment of CD38+ Malignancies Sammicheli S. et al.American Association for Cancer Research Annual Meetingarrow_green
10 Dec 2021ISB 1442Oral Presentation: Preclinical Data Summary: First-in-Class CD38 and CD47 Bispecific Antibody Innate Cell Modulator for Relapsed / Refractory Multiple Myeloma Sammicheli S. et al.American Society of Hematology Annual Meetingarrow_green
10 Dec 2021ISB 1442Oral Presentation: ISB 1442, a First-in-Class CD38 and CD47 Bispecific Antibody Innate Cell Modulator for the Treatment of Relapsed Refractory Multiple MyelomaSammicheli S. et al.Bloodarrow_green
04 Jun 2021ISB 1342Poster:ISB 1342, A First-In-Class CD38 T Cell Engager for the Treatment of Relapsed Refractory Multiple MyelomaDoucey, M.American Society of Clinical Oncology Annual Meetingarrow_green
03 May 2021ISB 830Telazorlimab in Atopic Dermatitis: Phase 2b Study Shows Improvement at 16 WeeksSher, L.2021 Society for Investigative Dermatology Virtual Meetingarrow_green
28 Jan 2021Cell Line DevelopmentGeneration of homogeneous cell populations with tunable levels of transgene expressionSchlicht D. et al.Journal of Biotechnologyarrow_green
13 May 2020BEAT® Antibody Engineering PlatformA single mutation increases heavy-chain heterodimer assembly of bispecific antibodies by inducing structural disorder in one homodimer speciesStutz C. et al.Journal of Biological Chemistryarrow_green
12 Sep 2019BEAT® Antibody Engineering PlatformSingle-step Protein A and Protein G avidity purification methods to support bispecific antibody discovery and developmentOllier R. et al.mAbsarrow_g</a>reen
06 Feb 2019ISB 830GBR 830, an anti-OX40, improves skin gene signatures and clinical scores in patients with atopic dermatitisGuttman-Yassky E. et al.Journal of Allergy and Clinical Immunologyarrow_green
27 Apr 2017BEAT® Antibody Engineering PlatformImmunoglobulin domain interface exchange as a platform technology for the generation of Fc heterodimers and bispecific antibodiesSkegro D. et al.Journal of Biological Chemistryarrow_green